Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.25 USD | -0.24% | -0.34% | -9.44% |
11/04 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
03/04 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.44% | 1.66B | |
+26.47% | 664B | |
+26.74% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.43% | 234B | |
+4.71% | 199B | |
-9.53% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences : Initiates Phase 2 Trial of Pitolisant to Treat Excessive Daytime Sleepiness; Shares Rise Early